NUVB - Nuvation Bio Inc

NUVB - Nuvation Bio Inc

https://www.nuvationbio.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Top 2 Health Care Stocks That May Plunge This Month - Esperion Therapeutics ( NASDAQ:ESPR ) , Enerflex ( NYSE:EFXT )

Benzinga • 1 week, 3 days ago • score: 0.32

As of Sept. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...

Nuvation Bio Inc. ( NUVB ) Just Flashed Golden Cross Signal: Do You Buy?

Zacks Commentary • 2 weeks, 5 days ago • score: 0.50

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Nuvation Bio Inc. ( NUVB ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.17

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +93.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Nuvation Bio ( NUVB ) Rating Upgrade to Buy

Zacks Commentary • 2 months ago • score: 0.36

Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nuvation Bio Inc. ( NUVB ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months, 1 week ago • score: 0.03

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0% and 23.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.

52W High

$4.09

52W Low

$1.54

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.37

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

2.23

EV/Revenue (<3 favorable)

54.68

P/S (TTM) (<3 favorable)

92.99

P/B (<3 favorable)

3.58

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

19.03%

Institutions (25–75% balanced)

66.70%

Shares Outstanding

341,273,000

Float

231,048,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

14,355,000

Gross Profit (TTM)

3,954,000

EPS (TTM)

-0.38

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-13.16%

ROE (TTM) (>15% strong)

-0.45%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

2.37

Momentum

Bearish momentum

Value

0.3247

Previous

0.2490

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025